Glaukos Corp (GKOS) CFO Sells $169,559.42 in Stock

Glaukos Corp (NYSE:GKOS) CFO Joseph E. Gilliam sold 2,603 shares of Glaukos stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $65.14, for a total transaction of $169,559.42. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Joseph E. Gilliam also recently made the following trade(s):

  • On Tuesday, February 19th, Joseph E. Gilliam sold 5,000 shares of Glaukos stock. The shares were sold at an average price of $70.03, for a total transaction of $350,150.00.

NYSE:GKOS traded up $1.63 on Thursday, reaching $68.88. 13,280 shares of the stock traded hands, compared to its average volume of 400,681. The firm has a market cap of $2.40 billion, a P/E ratio of -185.86 and a beta of 1.54. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.38 and a current ratio of 6.72. Glaukos Corp has a 12 month low of $33.36 and a 12 month high of $83.14.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The business had revenue of $54.03 million during the quarter, compared to analyst estimates of $50.13 million. Glaukos had a negative net margin of 5.93% and a negative return on equity of 6.90%. On average, equities research analysts predict that Glaukos Corp will post -0.3 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. NumerixS Investment Technologies Inc grew its stake in shares of Glaukos by 20.7% in the fourth quarter. NumerixS Investment Technologies Inc now owns 1,100 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 189 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Glaukos by 0.5% in the first quarter. JPMorgan Chase & Co. now owns 46,314 shares of the medical instruments supplier’s stock worth $3,630,000 after acquiring an additional 209 shares during the period. Equitable Trust Co. grew its stake in shares of Glaukos by 12.5% in the fourth quarter. Equitable Trust Co. now owns 4,500 shares of the medical instruments supplier’s stock worth $253,000 after acquiring an additional 500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Glaukos by 24.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,583 shares of the medical instruments supplier’s stock worth $145,000 after acquiring an additional 508 shares during the period. Finally, American International Group Inc. grew its stake in shares of Glaukos by 2.4% in the fourth quarter. American International Group Inc. now owns 22,433 shares of the medical instruments supplier’s stock worth $1,260,000 after acquiring an additional 530 shares during the period. Hedge funds and other institutional investors own 98.83% of the company’s stock.

GKOS has been the subject of a number of recent research reports. Piper Jaffray Companies reissued an “overweight” rating and set a $80.00 price target on shares of Glaukos in a research report on Thursday, February 28th. Stifel Nicolaus raised their price objective on shares of Glaukos from $58.00 to $68.00 and gave the company a “positive” rating in a research note on Thursday, February 28th. Zacks Investment Research lowered shares of Glaukos from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. BTIG Research restated a “hold” rating on shares of Glaukos in a research note on Friday, May 10th. Finally, BMO Capital Markets raised their price objective on shares of Glaukos from $66.00 to $71.00 and gave the company a “market perform” rating in a research note on Thursday, May 9th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $72.56.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2019/05/16/glaukos-corp-gkos-cfo-sells-169559-42-in-stock.html.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Featured Article: Determine Your Level of Risk Tolerance

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.